![]() |
15th International AIDS ConferenceBangkok, Thailand - July 11-16, 2004 |
Int Conf AIDS 2004 Jul 11-16; 15:(abstract no. TuOrB1149)
Fryland M, Chaillet P, Bonte L, Barnaba A, Teck R, Odiambo D, Zachariah R
Medecins sans Frontieres, Brussels, Belgium
BACKGROUND: It is important to monitor CD4+ T-Cell counts in HIV-positive individuals in order to decide when to initiate anti-retroviral treatment (ART) and to assess immunological evolution. A instrument called the Partec CyFlow Counter ó ä ó (Partec GmbH, Munster, Germany) is now available for CD4+ counting. This machine has particular advantages over other available CD4 counting machines; it is small and thus can be moved between different sites, it is able to function on a car battery, and the reagents are cheaper than that for other CD4 machines (FacsCount and FacsScan, BectDickinson). We evaluated if a) the Partec Cyflow Counter could be introduced into a routine district laboratory in Malawi and b)it would produce CD4 results of acceptable quality.
METHODS: The Cyflow counter was installed in a district laboratory in rural Malawi. During a 2 month period, consecutive blood samples from HIV-positive and negative individuals presenting to routine clinics were collected from 2 field sites and transported to the laboratory for CD4+ cell counting. The results were compared with a reference method, the FacsCount.
RESULTS: There were a total of 311 blood samples that were analyzed using both the Cyflow counter and the FacsCount. The CD4 count range in blood samples was 2 to 1789 cells/mul. The correlation coefficient for the Cyflow Counter was 0.92 (0.89-0.95). The mean difference in CD4 count values with FacsCount was -8.68 (-18.8 to 1.4). Intra-run variation was less than 3%. After being trained, local district laboratory staff found the Partec machine easy to manipulate and robust under routine field conditions.
CONCLUSIONS: The Partec CyFlow counter produces excellent results in a field setting and can be installed in a district hospital setting. It could provide HIV/AIDS programs with a new option for CD4+ monitoring in the context of scaling-up ART in resource-limited settings.
040711
TuOrB1149
Copyright © 2004 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.